Fluorouracil (5-Fluoracil, 5-FU)
- 貨號 Cat. No.
- S1209
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
Fluorouracil (5-Fluoracil, 5-FU)
Catalog No.S12091 Product Citations
Fluorouracil (5-Fluoracil, 5-FU) is an DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS).
| Size | Price | Stock | Quantity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | Fluorouracil (5-Fluoracil, 5-FU) is an DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS). | |||||
|---|---|---|---|---|---|---|
| Targets | ||||||
| IC50 | ||||||
| In vitro | Adrucil is an analogue of uracil with a fluorine atom at the C-5 position in place of hydrogen. It rapidly enters the cell using the same facilitated transport mechanism as uracil. Adrucil is converted intracellularly to several active metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). The Adrucil metabolite FdUMP binds to the nucleotide-binding site of TS, forming a stable ternary complex with the enzyme and CH2THF, thereby blocking binding of the normal substrate dUMP and inhibiting dTMP synthesis. Metabolite of Adrucil also can be misincorporated into DNA, leading to DNA strand breaks and cell death. The pro-apoptosis effects of Adrucil may be related to its activation of tumor suppressor p53. Loss of p53 function reduces cellular sensitivity to Adrucil. [1] Adrucil is able to inhibit the survival and induce apoptosis of a board range of cancer cells. Adrucil suppresses viabilities of the nasopharyngeal carcinoma cell line CNE2 and HONE1 [2], pancreatic cancer cell lines Capan-1 [3], and human colon carcinoma cell line HT-29 [4] with IC50 of 9 μg/mL, 3 μg/mL, 0.22 μM, 2.5 μM, respectively. | |||||
| In vivo | Adrucil is widely used in the treatment of a range of cancers, including colorectal and breast cancers. [1]100mg/kg Adrucil significantly suppresses tumor growth of murine colon carcinomas Colon 38 with tumor-doubling time (TD), growth-delay factor (GDF), and T/C of 26.5 days, 4.4, and 14%. [5] | |||||
| Features | ||||||
Protocol(Only for Reference)
Cell Assay: [4]
| Cell lines | Human colon carcinoma cell line HT-29 |
|---|---|
| Concentrations | ~25 μM |
| Incubation Time | 7 days |
| Method | Growth inhibition is measured after treatment of cells with Adrucil for 7 days in 96-well plates (4000 HT-29 cells/well in RPMI 1640 medium with 10% dialyzed fetal bovine serum); increasing concentrations of Adrucil are added after allowing for cell attachment overnight. At the end of incubation, cells are rinsed three times with phosphate-buffered saline (pH 7.4), fixed with 10% trichloroacetic acid for 60 min at 4 ℃, washed five times with deionized water, and stained with 0.4% sulforhoda-mine B solution for 15 min at room temperature. Unstained sulforhodamine B is removed by rinsing with 1% glacial acetic acid. Afterwards, stained cell proteins are dried and dissolved with 10 mM Tris-HCl. The optical density value is measured using a detector at 540 nm wavelength. |
Animal Study: [5]
| Animal Models | Murine colon carcinomas Colon 38 |
|---|---|
| Dosages | 100 mg/kg |
| Administration | i.p. weekly |
References
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02015650 | Not yet recruiting | Head and Neck Neoplasms | Medical University Innsbruck | 2014-01 | Phase 4 |
| NCT02016417 | Not yet recruiting | Nasopharyngeal Carcinoma | Cancer Hospital of Guangxi Medical University | 2014-01 | Phase 2 |
| NCT01992705 | Not yet recruiting | Resectable Pancreatic Cancer | University of Maryland | 2014-01 | Phase 0 |
| NCT02017704 | Not yet recruiting | Adenocarcinoma of the Prostate | Sidney Kimmel Comprehensive Cancer Center|Nucletron | 2014-02 | Phase 2 |
| NCT00960544 | Not yet recruiting | Breast Cancer | M.D. Anderson Cancer Center|Myriad Genetic Laboratories, Inc. | 2014-03 | Phase 2 |
Chemical Information
Download Fluorouracil (5-Fluoracil, 5-FU) SDF
| Molecular Weight (MW) | 130.08 |
|---|---|
| Formula | C4H3FN2O2 |
| CAS No. | 51-21-8 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | 5-FU, Carac, Efudex, Fluoroplex |
| Solubility (25°C) * | In vitro | DMSO | 26 mg/mL (199 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.13008 | 1.3008 | 2.6016 | 3.9024 |
Product Citations (1)